Your SlideShare is downloading. ×
0
Partnerships in drug discovery and
development for diseases of the
developing world
Ken Duncan
BioDundee, Dundee
29 May, 2...
2
TOPICS
1. Introduction to the work of the Bill &
Melinda Gates Foundation
2. Drug discovery portfolio
3. Importance of p...
3
TOPICS
1. Introduction to the work of the Bill &
Melinda Gates Foundation
2. Drug discovery portfolio
3. Importance of p...
© 2010 Bill & Melinda Gates Foundation |
Our Belief
ALL LIVES
—NO MATTER WHERE THEY ARE BEING LIVED—
HAVE EQUAL VALUE
Our History
Bill and Melinda
read an article
about rotavirus
They officially
create the
foundation
Warren Buffett
decides ...
$36.4 billion
Asset trust endowment
$26 billion
Grants Since inception
1,100
Employees worldwide
$3.4 billion
2012 grants ...
What We Focus On
What are
the areas
of greatest
need?
Where can
we have
the greatest
impact?
United States
Program
Global Health
Program
Global Development
Program
Programs
2011 Grants Paid Summary
For the year ended December 31, 2011. Amount in thousands.
(by Program Area)
Global Health $1,977...
Integrated Approach for Global Health
VACCINES
VECTOR CONTROL
SANITATION
FAMILY HEALTH
DRUGS
DIAGNOSTICS
How Our Strategies Align
All strategies seek
transformational change.
All strategies rely on partners and
grantees to carr...
TOPICS
1. Introduction to the work of the Bill &
Melinda Gates Foundation
2. Drug discovery portfolio
3. Importance of par...
Drug discovery priorities
Malaria Helminths
Diarrheal
Disease
TB
Platforms
Drug discovery priorities
Malaria
Bell et al. Nature Reviews Microbiology 4, S7–S20 (2006)SERCaP
(Single Encounter
Radical...
Drug discovery priorities
Helminths
Onchocerciasis: "River Blindness"
Lymphatic Filariasis: "Elephantiasis"
Macrofilaricid...
Drug discovery priorities
TB
Novel combination
Shorter, safer treatment
Overcome MDR-TB
Target Product Profile
Drug discovery priorities
Diarrheal
Disease
Adapted from The Global Burden of Disease: 2004 Update; WHO
Anti-secretory
Boo...
Drug discovery priorities
Platforms
Grantees and partners
Target Lead Candidate
Lead
Optimisation
Target
validation
Pre-clinical Clinical
Development
Lead
Ide...
TOPICS
1. Introduction to the work of the Bill &
Melinda Gates Foundation
2. Drug discovery portfolio
3. Importance of par...
TB treatment today
6-24 months
Multiple drugs
Isoniazid
Rifampicin
Pyrazinamide
Ethambutol
Complexity: DOTS
Safety, drug-d...
Bedaquiline, first new TB drug
approved in over 40 years
December 31, 2012
Importance of Partnerships
Target Lead Candidate
Lead
Optimisation
Target
validation
Pre-clinical Clinical
Development
Lea...
24
CPTR: A new development paradigm
TBDA
Next generation therapy
Goal:
A new first line drug regimen
that works in one month or less
Problem:
Few new drug can...
TBDA
The TBDA is a groundbreaking partnership between seven pharmaceutical companies and
six research institutions collabo...
TBDA
The TBDA is a New Paradigm For Drug Discovery
The TBDA offers a new approach that addresses many of the bottlenecks i...
TBDA
• Partnerships such as the TBDA show how industry and others can work
together in new ways to support global health i...
EVERY PERSON DESERVES THE
CHANCE TO LIVE A
HEALTHY, PRODUCTIVE LIFE.
All Rights Reserved. Bill & Melinda Gates Foundation is a registered trademark in the United States and other countries.
L...
Upcoming SlideShare
Loading in...5
×

Bill & Melinda Gates foundation - Ken Duncan

800

Published on

Partnerships in drug discovery and development for diseases of the developing world

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
800
On Slideshare
0
From Embeds
0
Number of Embeds
4
Actions
Shares
0
Downloads
34
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide
  • Broken up talk into three sections
  • Broken up talk into three sections
  • The Bill & Melinda Gates Foundation is a private foundation. The family decided to invest their resource to make their beliefs a reality , ALL LIVES NO MATTER WHERE THEY ARE BEING LIVED HAVE EQUAL VALUE. TRANSITION - This belief is the building blocks of our work.
  • More than a decade ago, Bill and Melinda read a newspaper article about the millions of children dying each year in poor countries from diseases that most people in the United States don’t have to worry about. One disease in particular—rotavirus—caught their attention. It was killing half a million children a year. They’d never even heard of rotavirus. They thought that that figure might be a typo. In 2006, Warren Buffett surprised them with a pledge of most of his shares in Berkshire Hathaway, doubling the foundation’s annual grantmaking and potential impact. In 2008,Bill made his transition from Microsoft, joining Melinda in a full-time role at the foundation. The foundation was established on Bill’s and Melinda’s passion to address some of the inequities in the world, with the premise that all lives, no matter where they are being lived, have equal value
  • Total 2012 Grant Payments: $3.4 billion (figure includes other direct charitable contributions of $234 million)Asset Trust Endowment: $36.4 billion (as of December, 31, 2012)Remaining Warren Buffet Pledge: $31.3 billion
  • To be successful, we have to focus on a set of problems. To do that, we ask two key questions.
  • Work divided into 3 main areasUS programs: education,libraries, and Pacific NWGlobal Development:Agricultural Development; Financial Services for the Poor; Water, Sanitation & Hygiene; Special InitiativesGlobal Health:harnesses advances in science and technology to save lives in poor countriesfocus on the health problems that have a major impact in developing countries but get too little attention and funding. Where proven tools exist, we support sustainable ways to improve their delivery. Where they don’t, we invest in research and development of new interventions, such as vaccines, drugs, and diagnostics. we allocate about half of our resources to our work in global health, a quarter to our work in the United States, and another quarter to our work in global development
  • To give you a sense of our scale and how we allocate these funds:Our endowment (as of Dec. 31, 2012) is $36.4 billion. We now employee over 1,100 people, and each year we give out about $3.4 billion in grants as of last year.This chart illustrates where our grants were made in 2011. You can see that Global Health received about 63 percent of our grantee funds with investments of more than $1.98 billion. Global Development grantees received $668 million while U.S. Program grantees received $487 million—about 21 percent and 16 percent of total program-related grants, respectively. While we are the largest charitable foundation in the world, we know that our money is a drop in the bucket compared to what is needed to solve these problems. For example, California’s public education annual budget is $57 billion annually. So, we see our funding as catalytic; we leverage our funds to bring even more funding and attention to issues.Recently, Bill and Melinda accelerated the timeline to sunset the foundation. Formerly 50 years, all resources will now be spent within 20 years of their deaths.
  • Summary of Changes with the Global ProgramsThat’s why we decided to create a new Global Programs structure to encourage a more integrated approach to our work. Program teams focused on areas ranging from agricultural development to vaccines are now working together more closely on the discovery and delivery of health and development innovations that will meet the many needs of the people we serve.Our goal is to maximize discovery and delivery in global health and development, as well as increase the relevance and impact of our in-country work. Working across Global Programs and engaging grantees and partners alike will increase our local-country insight—which ultimately helps us achieve greater results in the countries where we work and where the most intensive need exists.Integrated ApproachOur new Global Programs structure aims to meet the many needs of the people we serve:Agricultural Development - Helping poor farm families to grow and sell more food reduces hunger and poverty.Family Planning - Family planning can significantly improve the health and welfare of women and their families.Nutrition - Proper nutrition during pregnancy and in early childhood improves children's health and the quality of their lives for years to come.Malaria - Access to drugs and tools to prevent and treat malaria have saved and improved the lives of millions of families around the world.Vaccines - Vaccines work to save and improve lives and protect children for a lifetime.Sanitation - Improved sanitation increases productivity, reduces healthcare costs, and prevents illness, disability, and early death.
  • All of our strategies seek enduring, transformational change in people’s lives by discovering tools and approaches that can achieve results on a broad scale.All of our strategies rely on partners and grantees to carry out the work in the field.All of our strategies make use of technology to advance our work—whether it’s online learning tools that help students progress at their own pace, GPS mapping technology to help vaccination teams in the field, or new contraceptive technologies that are cheaper and easier for women to use.
  • Broken up talk into three sections
  • Broken up talk into three sections
  • Current TB regimens drive down bacterial levels quickly, but require months of treatment to rid the body of all TB……The only way to overcome this persistence is through ashorter, more effective regimen
  • Bill and Melinda Gates started the foundation because they believe every person should have the chance to live a healthy and productive life. This belief underlies all of the foundation’s work to reduce hunger, poverty, and disease around the globe.
  • Transcript of "Bill & Melinda Gates foundation - Ken Duncan"

    1. 1. Partnerships in drug discovery and development for diseases of the developing world Ken Duncan BioDundee, Dundee 29 May, 2013
    2. 2. 2 TOPICS 1. Introduction to the work of the Bill & Melinda Gates Foundation 2. Drug discovery portfolio 3. Importance of partnerships in TB drug discovery and development
    3. 3. 3 TOPICS 1. Introduction to the work of the Bill & Melinda Gates Foundation 2. Drug discovery portfolio 3. Importance of partnerships in TB drug discovery and development
    4. 4. © 2010 Bill & Melinda Gates Foundation | Our Belief ALL LIVES —NO MATTER WHERE THEY ARE BEING LIVED— HAVE EQUAL VALUE
    5. 5. Our History Bill and Melinda read an article about rotavirus They officially create the foundation Warren Buffett decides to give Berkshire Hathaway stock 1998 2000 2006 2008 Bill joins Melinda full-time at the foundation
    6. 6. $36.4 billion Asset trust endowment $26 billion Grants Since inception 1,100 Employees worldwide $3.4 billion 2012 grants payments $31.3 billion Warren Buffet pledge Headquarters: Seattle Offices: London, Washington DC Country Offices: China, India Country Representatives: Ethiopia, South Africa, Nigeria Reach & Presence
    7. 7. What We Focus On What are the areas of greatest need? Where can we have the greatest impact?
    8. 8. United States Program Global Health Program Global Development Program Programs
    9. 9. 2011 Grants Paid Summary For the year ended December 31, 2011. Amount in thousands. (by Program Area) Global Health $1,977,507 Global Development $667,780 United States Program $486,917 Operations/Non-Program Grants $48,466 Strategic Media Partnerships $18,379 Policy & Government Affairs $9,117
    10. 10. Integrated Approach for Global Health VACCINES VECTOR CONTROL SANITATION FAMILY HEALTH DRUGS DIAGNOSTICS
    11. 11. How Our Strategies Align All strategies seek transformational change. All strategies rely on partners and grantees to carry out the work. All strategies emphasize technology.
    12. 12. TOPICS 1. Introduction to the work of the Bill & Melinda Gates Foundation 2. Drug discovery portfolio 3. Importance of partnerships in TB drug discovery and development
    13. 13. Drug discovery priorities Malaria Helminths Diarrheal Disease TB Platforms
    14. 14. Drug discovery priorities Malaria Bell et al. Nature Reviews Microbiology 4, S7–S20 (2006)SERCaP (Single Encounter Radical Cure and Prophylaxis) Target Product Profile
    15. 15. Drug discovery priorities Helminths Onchocerciasis: "River Blindness" Lymphatic Filariasis: "Elephantiasis" Macrofilaricide Kill Adult worms Safe in Loa loa regions Target Product Profile
    16. 16. Drug discovery priorities TB Novel combination Shorter, safer treatment Overcome MDR-TB Target Product Profile
    17. 17. Drug discovery priorities Diarrheal Disease Adapted from The Global Burden of Disease: 2004 Update; WHO Anti-secretory Boost ORS effectiveness Increase ORS compliance Target Product Profile
    18. 18. Drug discovery priorities Platforms
    19. 19. Grantees and partners Target Lead Candidate Lead Optimisation Target validation Pre-clinical Clinical Development Lead Identification Target identification Product Development Partnerships Academia, Institutes Pharma Biotech
    20. 20. TOPICS 1. Introduction to the work of the Bill & Melinda Gates Foundation 2. Drug discovery portfolio 3. Importance of partnerships in TB drug discovery and development
    21. 21. TB treatment today 6-24 months Multiple drugs Isoniazid Rifampicin Pyrazinamide Ethambutol Complexity: DOTS Safety, drug-drug interactions The World needs a shorter, safer drug regimen
    22. 22. Bedaquiline, first new TB drug approved in over 40 years December 31, 2012
    23. 23. Importance of Partnerships Target Lead Candidate Lead Optimisation Target validation Pre-clinical Clinical Development Lead Identification Target identification TBDA CPTR
    24. 24. 24
    25. 25. CPTR: A new development paradigm
    26. 26. TBDA Next generation therapy Goal: A new first line drug regimen that works in one month or less Problem: Few new drug candidates, little diversity Solution: An integrated cross-industry- academia discovery partnership Challenge:
    27. 27. TBDA The TBDA is a groundbreaking partnership between seven pharmaceutical companies and six research institutions collaborating on early TB drug discovery The TB Drug Accelerator How it works… Company Compound Libraries Collaborative Discovery Research 5 new preclinical candidates 2016 1 month regimen proof of concept 2021 • Hit and Lead Generation • Target Identification • Lead Optimization Research Institutions: Pharmaceutical Companies: With support from:
    28. 28. TBDA The TBDA is a New Paradigm For Drug Discovery The TBDA offers a new approach that addresses many of the bottlenecks in the way TB drugs are currently developed ONLY THE BEST CANDIDATES ADVANCE Early Collaboration Avoid Redundancy Data Sharing Maximize Efficiency Overcome Competitive Barriers Companies Work on Each Other’s Compounds
    29. 29. TBDA • Partnerships such as the TBDA show how industry and others can work together in new ways to support global health innovation • The TBDA model could be applied to other disease areas that lack incentives for research or require combination drug therapies The TBDA Offers a Model for Other Initiatives
    30. 30. EVERY PERSON DESERVES THE CHANCE TO LIVE A HEALTHY, PRODUCTIVE LIFE.
    31. 31. All Rights Reserved. Bill & Melinda Gates Foundation is a registered trademark in the United States and other countries. Learn More www.GatesFoundation.org www.ImpatientOptimists.org BillandMelindaGatesFoundation @GatesFoundation
    1. A particular slide catching your eye?

      Clipping is a handy way to collect important slides you want to go back to later.

    ×